

RUNDC3A (h): 293T Lysate: sc-370464

BACKGROUND

RUNDC3A (RUN domain containing 3A), also known as RPIP-8 (Rap2-interacting protein 8) or RAP2IP, is a 446 amino acid protein that is thought to act as an effector protein of RAP2A in neuronal cells. A member of the RUNDC3 family, RUNDC3A contains one RUN domain and undergoes alternative splicing events to produce four isoforms. RUNDC3A is expressed in testis, brain, kidney and liver, and is encoded by a gene that maps to human chromosome 17q21.31. Chromosome 17 comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes.

REFERENCES

1. Hall, J.M., Friedman, L., Guenther, C., Lee, M.K., Weber, J.L., Black, D.M. and King, M.C. 1992. Closing in on a breast cancer gene on chromosome 17q. *Am. J. Hum. Genet.* 50: 1235-1242.
2. Evans, S.C. and Lozano, G. 1997. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. *Mol. Med. Today* 3: 390-395.
3. Varley, J.M., Thorncroft, M., McGown, G., Appleby, J., Kelsey, A.M., Tricker, K.J., Evans, D.G. and Birch, J.M. 1997. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. *Oncogene* 14: 865-871.
4. Kersemaekers, A.M., Hermans, J., Fleuren, G.J. and van de Vijver, M.J. 1998. Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. *Br. J. Cancer* 77: 192-200.
5. Janoueix-Lerosey, I., Pasheva, E., de Tand, M.F., Tavitian, A. and de Gunzburg, J. 1998. Identification of a specific effector of the small GTP-binding protein Rap2. *Eur. J. Biochem.* 252: 290-298.
6. Soussi, T., Dehouche, K. and Bérout, C. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. *Hum. Mutat.* 15: 105-113.
7. Piura, B., Rabinovich, A. and Yanai-Inbar, I. 2001. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 97: 241-244.
8. Minamoto, T., Buschmann, T., Habelhah, H., Matusevich, E., Tahara, H., Boerresen-Dale, A.L., Harris, C., Sidransky, D. and Ronai, Z. 2001. Distinct pattern of p53 phosphorylation in human tumors. *Oncogene* 20: 3341-3347.
9. Online Mendelian Inheritance in Man, OMIM™. 2010. Johns Hopkins University, Baltimore, MD. MIM Number: 605448. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: RUNDC3A (human) mapping to 17q21.31.

PRODUCT

RUNDC3A (h): 293T Lysate represents a lysate of human RUNDC3A transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

RUNDC3A (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive RUNDC3A antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.